Kernal Biologics Presenting Results at the 9th Annual mRNA Health Conference CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Kernal Biologics, Inc. (Kernal Bio) — an early-development-stage mRNA-technology company developing cancer therapeutics designed to improve...

PV-10® Abstract Previously Accepted for Presentation at Terminated American Association for Cancer Research (AACR) Annual Meeting 2020 KNOXVILLE, TN, March 17, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today said that data from ongoing research into investigational lysosomal-targeting cancer immunotherapy PV-10 (rose bengal...

PROVECTUS BIOPHARMACEUTICALS ANNOUNCES CHANGES TO BOARD OF DIRECTORS FOR IMMEDIATE RELEASE Ed Pershing, CPA elected new Board chair Jack Lacey, MD named new Board director; also appointed new strategic advisory board chair KNOXVILLE, TN, April 24, 2018 ...

SECOND STUDY OF EXPANDED ACCESS PATIENTS TREATED WITH PV-10 FOR IN-TRANSIT MELANOMA PUBLISHED IN JOURNAL OF SURGICAL ONCOLOGY FOR IMMEDIATE RELEASE KNOXVILLE, TN, April 19, 2018 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (“Provectus” or the “Company”), a...